Gilead/Galapagos alliance hit again as IPF drug is binnedGilead and Galapagos’ much-trumpeted R&D alliance has suffered another setback with the abandonment of ziritaxestat after a late-stage Share XGilead/Galapagos alliance hit again as IPF drug is binnedhttps://pharmaphorum.com/news/gilead-galapagos-alliance-hit-again-as-ipf-drug-is-binned/
Interstitial Lung Disease (ILD) Drug Development SummitIndustry Led Conference on Fibrosing ILDs Share XInterstitial Lung Disease (ILD) Drug Development Summithttps://pharmaphorum.com/events/interstitial-lung-disease-ild-drug-development-summit/
BMS swoops on Forbius, snaring another immuno-oncology playerWith the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development Share XBMS swoops on Forbius, snaring another immuno-oncology playerhttps://pharmaphorum.com/news/bms-swoops-on-forbius-snaring-another-immuno-oncology-player/
BMS, BioMotiv alliance generates biopharma company AnterosA partnership between Bristol-Myers Squibb and drug development accelerator BioMotiv has yielded its first fruit just a few Share XBMS, BioMotiv alliance generates biopharma company Anteroshttps://pharmaphorum.com/news/bms-biomotiv-alliance-generates-biopharma-company-anteros/
The promising future of RNARNA technology-based therapeutics are a new and novel way to treat diseases. RNA medicines utilise biological processes to Share XThe promising future of RNAhttps://pharmaphorum.com/r-d/views-analysis-r-d/the-promising-future-of-rna/
BMS begins Harvard fibrosis stem cell research collaborationR&D link-up with Harvard Fibrosis Network Share XBMS begins Harvard fibrosis stem cell research collaborationhttps://pharmaphorum.com/news/bms-begins-harvard-fibrosis-stem-cell-research-collaboration/